FindTrial
Sign In

Acute lipid profile changes in malaria patients - a gateway towards novel antimalarial drug class identification?

Acute lipid profile changes in malaria patients - a gateway towards novel antimalarial drug class identification? - Lipomal

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON44881
Enrollment
180
Registered
2014-01-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

jungle fever Tropical fever

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients > 18 jaar gedianosticeerd met malaria Controls > 18 jaar with acute symptoms

Exclusion criteria

Exclusion criteria: chronic lipid metabolic disorder chronic use of medication

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is the plasma lipid profile. Full plasma lipid analyses (total cholesterol, HDL, apolipoprotein A1, LDL, VLDL and triglycerides) will be conducted in both maparia patient and control groups.—

Secondary

MeasureTime frame
The secondary outcome measures in the patient group are hemozoin quantity proxies as outlined above, in correlation with parasite density, and clinical characteristics as obtained in the framework of routine clinical care.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)